15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Innate Pharma, 2 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $2.00 to $9.00 (about 4.5x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $6.00 sits 165% above the current $2.26. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.09 next quarter toward $-0.63 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy267%
Hold133%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Innate Pharma.
As of Aug, 2 of 3 firms rate IPHA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IPHA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.09
Range $-0.09 – $-0.09 · 1 analysts
Next period, 1 analysts expect Innate Pharma to earn $-0.09 a share (range $-0.09 – $-0.09), versus — a year earlier. Full-year consensus is $-0.09, growing to $-0.63 the year after.
REVENUE · NEXT QUARTER
—
Range — – — · 1 analysts
Revenue is expected to reach — (range — – —). Full-year consensus is $66.4M, rising to $96.6M next year.
Top analysts covering Innate Pharma
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IPHA.
#1
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #243
Buy
$7.00+209.7% to target
Overall win rate
38%
+ Follow
#2
Daina Graybosch
Leerink Partners · Rank #322
Hold
$2.00-11.5% to target
Overall win rate
40%
+ Follow
#3
JM
Jeet Mukherjee
BTIG
Buy
$9.00+298.2% to target
Coverage
—
+ Follow
#4
Justin Zelin
BTIG
Buy
$8.00+254.0% to target
Coverage
—
+ Follow
IPHA stock forecast FAQ
What is IPHA's average 12-month price target?+
The 3 analysts with a live target average $6.00 for Innate Pharma over the next 12 months, ranging from a $9.00 high to a $2.00 low.
Is IPHA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 2 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IPHA?+
The Street-high target is $9.00 (BTIG), and the Street-low is $2.00 (Leerink Partners). The average of all 3 active targets is $6.00.
How many Wall Street analysts cover IPHA?+
3 analysts have an active rating on Innate Pharma, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering IPHA?+
Among analysts who currently cover IPHA, Swayampakula Ramakanth of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #243). Their current call is Buy with a $7.00 target.
What is Innate Pharma's projected EPS for next quarter?+
The consensus estimate is $-0.09 per share (range $-0.09 – $-0.09) across 1 analysts. Full-year EPS is projected at $-0.09, rising to $-0.63 the following year.
How much revenue is Innate Pharma expected to report next quarter?+
Consensus revenue is — (range — – —). Full-year revenue is projected at $66.4M, growing to $96.6M next year.
Have analysts been upgrading or downgrading IPHA lately?+
As of Aug, 2 of 3 firms rate IPHA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IPHA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
